ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
877-355-1989
-Chronic low back pain ≥3 months in duration, Quebec Task Force in Spinal Disorders class 1 or 2, with documented history of previous inadequate treatment response to at least 3 different categories of agents commonly used and generally considered effective for the treatment of chronic low back pain.
--Diagnosis of osteoarthritis of the knee or hip as defined by the American College of
Rheumatology (ACR) criteria.
- Subjects who have Kellgren Lawrence Grade > or =2 radiographic evidence of hip or
Grade > or=3 radiographic evidence of knee osteoarthritis will be excluded;
- History or radiographic evidence of other diseases that could confound efficacy or
safety assessments (e.g., rheumatoid arthritis).
- History or radiographic evidence of orthopedic conditions that may increase the risk
of, or confound assessment of joint safety conditions during the study.
- Signs and symptoms of clinically significant cardiac disease within 6 months of the
study (e.g., unstable angina, myocardial infarction, resting bradycardia, poorly
controlled or untreated hypertension) as defined in the protocol or subjects with any
other cardiovascular illness that in the opinion of the Investigator would render a
subject unsuitable to participate in the study
- History, diagnosis, or signs and symptoms of clinically significant neurological
disease (e.g., transient ischemic attack, stroke, peripheral or autonomic neuropathy)
as specified in the protocol
- Subjects with evidence or symptoms consistent with autonomic dysfunction (e.g.,
orthostatic hypotension and/or autonomic symptoms) as defined in the protocol.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- Funabashi-shi, Chiba
- Funabashi, Chiba
- Matsudo-shi, Chiba
- Fukuoka-shi, Fukuoka
- Chitose, Hokkaido
- Sapporo-shi, Hokkaido
- Sapporo, Hokkaido
- Katougun, Hyogo
- Kobe, Hyogo
- Nishinomiya, Hyogo
- Sagamihara-shi, Kanagawa
- Yokohama-shi, Kanagawa
- Yokohama, Kanagawa
- Hatogaya-shi, Saitama
- Kumagaya-shi, Saitama
- Kumagayashi, Saitama
- Minamisaitama-gun, Saitama
- Saitama-shi, Saitama
- Tokorozawa, Saitama
- Adachi-Ku, Tokyo
- Bunkyou-ku, Tokyo
- Edogawa-ku, Tokyo
- Itabashi-ku, Tokyo
- Koito-ku, Tokyo
- Meguro-Ku, Tokyo
- Nakano-ku, Tokyo
- Nerima-ku, Tokyo
- Ota-Ku, Tokyo
- Ota-Ku, Tokyo
- Setagaya-ku, Tokyo
- Shibuya-ku, Tokyo
- Shinagawa-ku, Tokyo
- Shinjyuku-ku, Tokyo
- Suginami-ku, Tokyo
- Sumida-ku, Tokyo
- Toyoshima-ku, Tokyo
- Chiba,
- Fukuoka,
- Fukuoka,
- Tokyo,
- Anniston, Alabama
- Hueytown, Alabama
- Huntsville, Alabama
- Mobile, Alabama
- Chandler, Arizona
- Peoria, Arizona
- Phoenix, Arizona
- Scottsdale, Arizona
- Tempe, Arizona
- Tempe, Arizona
- Little Rock, Arkansas
- Burbank, California
- Fresno, California
- Garden Grove, California
- La Jolla, California
- Los Gatos, California
- Oceanside, California
- Rancho Mirage, California
- Roseville, California
- Sacramento, California
- San Diego, California
- Upland, California
- Windomar, California
- Boulder, Colorado
- Colorado Springs, Colorado
- Stamford, Connecticut
- Trumbull, Connecticut
- Chiefland, Florida
- DeFuniak Springs, Florida
- DeLand, Florida
- Jacksonville, Florida
- Naples, Florida
- Orlando, Florida
- Pembroke Pines, Florida
- Pinellas Park, Florida
- South Miami, Florida
- St. Petersburg, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Blue Ridge, Georgia
- Marietta, Georgia
- Boise, Idaho
- Evansville, Indiana
- Prairie Village, Kansas
- Topeka, Kansas
- Lexington, Kentucky
- Madisonville, Kentucky
- Monroe, Louisiana
- Baltimore, Maryland
- Worcester, Massachusetts
- Biloxi, Mississippi
- Jackson, Mississippi
- Springfield, Missouri
- St. Louis, Missouri
- St. Louis, Missouri
- Omaha, Nebraska
- Omaha, Nebraska
- Las Vegas,, Nevada
- Las Vegas, Nevada
- Berlin, New Jersey
- Willingboro, New Jersey
- Albuquerque, New Mexico
- Manlius, New York
- New York, New York
- New York, New York
- Rochester, New York
- Rochester, New York
- Williamsville, New York
- Greensboro, North Carolina
- Lenoir, North Carolina
- Raleigh, North Carolina
- Winston-Salem, North Carolina
- Cleveland, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Medford, Oregon
- Portland, Oregon
- Altoona, Pennsylvania
- Bridgeville, Pennsylvania
- Duncansville, Pennsylvania
- Philadelphia, Pennsylvania
- Cranston, Rhode Island
- Warwick, Rhode Island
- Columbia, South Carolina
- Greer, South Carolina
- Rapid City, South Dakota
- Germantown, Tennessee
- Johnson City, Tennessee
- Austin, Texas
- Beaumont, Texas
- Beaumont, Texas
- Bryan, Texas
- Carroltown, Texas
- Dallas, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Nassau Bay, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Charlottesville, Virginia
- Norfolk, Virginia
- Richmond, Virginia
- Virginia Beach, Virginia
- Bellevue, Washington
- Bs. As.,
- Buenos Aires,
- Goiania, Goias
- Curitiba, Parana
- Curitiba, PR
- Petropolis, Rio de Janeiro
- Sao Paulo, SP
- Sao Paulo, SP
- Sao Paulo, SP
- Sao Paulo,
- Santiago,
- Bogota, D.c.
- Bogota D.c,
- Cali-valle,
- Cartago City, Cartago
- Hatillo, San Jose
- Quito, Pichincha
- Toluca, Edo. de Mexico
- Zapopan, Jalisco
- Zapopan, Jalisco
- Puebla,
- Puebla,
- Puebla,
- Lima,
- Lima,
- Caracas, DF
- Caracas, DF
- Caracas, DF
- Caracas,
- Anniston, Alabama
- Hueytown, Alabama
- Mobile, Alabama
- Chandler, Arizona
- Peoria, Arizona
- Phoenix, Arizona
- Phoenix, Arizona
- Scottsdale, Arizona
- Tempe, Arizona
- Tempe, Arizona
- Tucson, Arizona
- Little Rock, Arkansas
- Burbank, California
- Fresno, California
- Garden Grove, California
- La Jolla, California
- Los Gatos, California
- Oceanside, California
- Rancho Mirage, California
- Roseville, California
- Sacramento, California
- San Diego, California
- Upland, California
- Windomar, California
- Stamford, Connecticut
- Trumbull, Connecticut
- Chiefland, Florida
- DeFuniak Springs, Florida
- DeLand, Florida
- Fort Lauderdale, Florida
- Jacksonville, Florida
- Naples, Florida
- Orlando, Florida
- Pembroke Pines, Florida
- Pinellas Park, Florida
- South Miami, Florida
- St. Petersburg, Florida
- West Palm Beach, Florida
- Atlanta, Georgia
- Blue Ridge, Georgia
- Marietta, Georgia
- Boise, Idaho
- Evansville, Indiana
- Overland Park, Kansas
- Prairie Village, Kansas
- Topeka, Kansas
- Lexington, Kentucky
- Madisonville, Kentucky
- Monroe, Louisiana
- Baltimore, Maryland
- Worcester, Massachusetts
- Lansing, Michigan
- Biloxi, Mississippi
- Jackson, Mississippi
- St. Louis, Missouri
- Omaha, Nebraska
- Omaha, Nebraska
- Las Vagas, Nevada
- Las Vegas, Nevada
- Berlin, New Jersey
- Willingboro, New Jersey
- Albuquerque, New Mexico
- Manlius, New York
- New York, New York
- New York, New York
- Rochester, New York
- Rochester, New York
- Williamsville, New York
- Greensboro, North Carolina
- Lenoir, North Carolina
- Raleigh, North Carolina
- Winston-Salem, North Carolina
- Cincincinati, Ohio
- Cincinnati, Ohio
- Cleveland, Ohio
- Oklahoma City, Oklahoma
- Oklahoma City, Oklahoma
- Medford, Oregon
- Portland, Oregon
- Altoona, Pennsylvania
- Bethlehem, Pennsylvania
- Bridgeville, Pennsylvania
- Duncansville, Pennsylvania
- Philadelphia, Pennsylvania
- Cranston, Rhode Island
- Warwick, Rhode Island
- Columbia, South Carolina
- Greer, South Carolina
- Rapid City, South Dakota
- Germantown, Tennessee
- Johnson City, Tennessee
- Austin, Texas
- Austin, Texas
- Beaumont, Texas
- Bryan, Texas
- Carroltown, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Houston, Texas
- Nassau Bay, Texas
- San Antonio, Texas
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Charlottesville, Virginia
- Norfolk, Virginia
- Richmond, Virginia
- Virginia Beach, Virginia
- Bellevue, Washington
Descriptive Information | |||||||
---|---|---|---|---|---|---|---|
Brief Title ICMJE | A Phase 3 Study of Tanezumab for Chronic Low Back Pain | ||||||
Official Title ICMJE | A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO AND ACTIVE-CONTROLLED, MULTICENTER, PARALLEL-GROUP STUDY OF THE ANALGESIC EFFICACY AND SAFETY OF TANEZUMAB IN ADULT SUBJECTS WITH CHRONIC LOW BACK PAIN | ||||||
Brief Summary | This study will investigate the efficacy and safety of tanezumab 5 mg and 10 mg administered by subcutaneous injection seven times at 8 week intervals (56 weeks). The primary objective of this study is to evaluate the effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. Secondary objectives are to evaluate the long-term safety and effectiveness of tanezumab 10 mg and 5 mg compared to placebo for the treatment of chronic low back pain. In addition, the study will evaluate the effectiveness and long term safety profile of tanezumab treatment for chronic low back pain compared to tramadol Prolonged Release (PR), a medication commonly utilized for the treatment of chronic low back pain. | ||||||
Detailed Description | This is a randomized, double blind, placebo and active controlled, multicenter, parallel group Phase 3 study of the efficacy and safety of tanezumab when administered by SC injection for up to 56 weeks in subjects with chronic low back pain. Approximately 1800 subjects will be randomized to 1 of 4 treatment groups in a 2:2:2:3 ratio (ie, 400 subjects per treatment group for the placebo, tanezumab 5 mg and tanezumab 10 mg treatment groups and 600 subjects in the tramadol PR treatment group). Treatment groups will include: 1.) Placebo administered SC at an 8 week interval plus placebo matching tramadol PR up to Week 16. At the Week 16 visit, subjects in this group who meet the efficacy responder criteria will be switched in a blinded fashion in a 1:1 ratio to either tanezumab 5 mg or tanezumab 10 mg administered SC at an 8 week interval plus placebo matching tramadol PR to Week 56; 2.)Tanezumab 5 mg SC administered at an 8 week interval plus placebo matching tramadol PR to Week 56; 3.) Tanezumab 10 mg SC administered at an 8 week interval plus placebo matching tramadol PR to Week 56; 4.) Oral tramadol PR plus placebo administered SC at an 8 week interval to Week 56. The study is designed with a total duration (post randomization) of up to 80 weeks and will consist of three periods: Screening (up to a maximum of 37 days; includes a Washout Period and an Initial Pain Assessment Period), a Double blind Treatment Period (comprised of a 16 week Primary Efficacy Phase and a 40 week Long Term Safety and Efficacy Phase), and a Follow up Period (24 weeks). The Screening Period (beginning up to 37 days prior to Randomization) includes a Washout Period (lasting 2 32 days), if required, and an Initial Pain Assessment Period (the 5 days prior to Randomization/Baseline). Prior to entering the study, subjects must have a documented history of previous inadequate treatment response to medications in 3 different categories of agents commonly used to treat and generally considered effective for the treatment of chronic low back pain. | ||||||
Study Type ICMJE | Interventional | ||||||
Study Phase ICMJE | Phase 3 | ||||||
Study Design ICMJE | Allocation: Randomized Intervention Model: Parallel Assignment Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) Primary Purpose: Treatment | ||||||
Condition ICMJE | Low Back Pain | ||||||
Intervention ICMJE |
| ||||||
Study Arms ICMJE |
| ||||||
Publications * | Markman JD, Bolash RB, McAlindon TE, Kivitz AJ, Pombo-Suarez M, Ohtori S, Roemer FW, Li DJ, Viktrup L, Bramson C, West CR, Verburg KM. Tanezumab for chronic low back pain: a randomized, double-blind, placebo- and active-controlled, phase 3 study of efficacy and safety. Pain. 2020 Sep 1;161(9):2068-2078. doi: 10.1097/j.pain.0000000000001928. | ||||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||||
Recruitment Information | |||||||
Recruitment Status ICMJE | Completed | ||||||
Actual Enrollment ICMJE | 1832 | ||||||
Original Estimated Enrollment ICMJE | 1800 | ||||||
Actual Study Completion Date ICMJE | December 20, 2018 | ||||||
Actual Primary Completion Date | October 17, 2017 (Final data collection date for primary outcome measure) | ||||||
Eligibility Criteria ICMJE | Inclusion Criteria: -Chronic low back pain ?3 months in duration, Quebec Task Force in Spinal Disorders class 1 or 2, with documented history of previous inadequate treatment response to at least 3 different categories of agents commonly used and generally considered effective for the treatment of chronic low back pain. Exclusion Criteria: --Diagnosis of osteoarthritis of the knee or hip as defined by the American College of Rheumatology (ACR) criteria.
| ||||||
Sex/Gender ICMJE |
| ||||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||||
Accepts Healthy Volunteers ICMJE | No | ||||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||||
Listed Location Countries ICMJE | Canada, Denmark, France, Hungary, Japan, Korea, Republic of, Spain, Sweden, United States | ||||||
Removed Location Countries | |||||||
Administrative Information | |||||||
NCT Number ICMJE | NCT02528253 | ||||||
Other Study ID Numbers ICMJE | A4091059 2012-005495-34 ( EudraCT Number ) CLBP SC STUDY ( Other Identifier: Alias Study Number ) A4091059 ( Other Identifier: Pfizer ) TANGO ( Other Identifier: Alias Study Number ) | ||||||
Has Data Monitoring Committee | Yes | ||||||
U.S. FDA-regulated Product |
| ||||||
IPD Sharing Statement ICMJE |
| ||||||
Responsible Party | Pfizer | ||||||
Study Sponsor ICMJE | Pfizer | ||||||
Collaborators ICMJE | Eli Lilly and Company | ||||||
Investigators ICMJE |
| ||||||
PRS Account | Pfizer | ||||||
Verification Date | February 2020 | ||||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |